ADVANCED SOLID TUMORS HARBORING KRAS G12C MUTATION

Clinical trials for ADVANCED SOLID TUMORS HARBORING KRAS G12C MUTATION explained in plain language.

Never miss a new study

Get alerted when new ADVANCED SOLID TUMORS HARBORING KRAS G12C MUTATION trials appear

Sign up with your email to follow new studies for ADVANCED SOLID TUMORS HARBORING KRAS G12C MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New hope for tough cancers: experimental combo targets KRAS mutation

Disease control Recruiting now

This early-stage study is testing whether adding an experimental drug called BAY3498264 to an existing cancer drug (sotorasib) can work better against advanced solid tumors with a specific KRAS mutation. Researchers want to find the safest dose of this combination and see if it h…

Matched conditions: ADVANCED SOLID TUMORS HARBORING KRAS G12C MUTATION

Phase: PHASE1 • Sponsor: Bayer • Aim: Disease control

Last updated Mar 30, 2026 14:30 UTC

ADVANCED SOLID TUMORS HARBORING KRAS G12C MUTATION

Get alerted when new ADVANCED SOLID TUMORS HARBORING KRAS G12C MUTATION trials appear

New hope for tough cancers: experimental combo targets KRAS mutation